

## SIMPONI ARIA (GOLIMUMAB) PATIENT REFERRAL AND PRESCRIPTION SHEET

	Pati	ent Information				
Patient Name:			Date:			
DOB:			Height:	🗅 inches 🗅 cm		
Allergies:			Weight:	🗆 lbs 🖵 kg		
Primary Diagnosis						
Diagnosis ICD-10 Diagnosis				ICD-10		
Rheumatoid arthritis	M45	Rheumatoid arthritis w	Rheumatoid arthritis with rheumatoid factor, unspecified M05.9			
Rheumatoid arthritis, unspecified	M06.9	Rheumatoid arthritis w	theumatoid arthritis w/o rheumatoid factor, unspecified M06.00			
Juvenile rheumatoid polyarthritis (seronegative)	M08.3	Other juvenile arthritis	her juvenile arthritis, unspecified site M08.80			
Psoriatic Arthritis	L40.52	Giller:				
Ankylosing Spondylitis	M45					
Medication Order						
Simponi Aria (Golimumab):         2mg/kg IV at weeks 0,4 and then every 8 weeks x 1 year (initial dosing)         2mg/kg IV every 8 weeks x 1 year         Other				from date signature indicated	<ul> <li>Refills x one year from date of signature unless indicated below</li> <li> Refills</li> </ul>	
Ancillary Orders						
<ul> <li>Pre-medications:</li> <li>Diphenhydramine: 25mg PO 30 min pre-infusion</li> <li>Acetaminophen: 650mg PO 30 min pre-infusion</li> <li>Famotidine: 20 mg PO x1 dose</li> <li>Other pre-meds:</li></ul>	Implanted VAD post-lab draw. H	<ul> <li>IV Flush Orders:</li> <li>Peripheral: NS 1-3 mL before/after use</li> <li>Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush</li> <li>CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush</li> <li>Refill x one year</li> </ul>				
Refill x one year		Heparin (10 uni	10 mL before/after use and 10 ts/mL) 3 to 5 mL final flush		aw	
<ul> <li>Refill x one year</li> <li>Anaphylaxis Protocol: Epinephrine Auto-Injector dua Administer epinephrine IM in the event of anaphylaxis</li> </ul>	•	Heparin (10 uni <b>Refill x one yea</b> 0.3mg Children: 0.15 mg	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r		aw	
Anaphylaxis Protocol: Epinephrine Auto-Injector dua	•	Heparin (10 uni <b>Refill x one yea</b> 0.3mg Children: 0.15 mg	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r	) mL post-lab dr	aw	
Anaphylaxis Protocol: Epinephrine Auto-Injector dua Administer epinephrine IM in the event of anaphylaxis	. May repeat x usion. If no res	Heparin (10 uni Refill x one year 0.3mg Children: 0.15 mg (1 as needed, Call 911. Refined sults Builts H&P OR progre Medication List	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r efill x 1yr Other Required Documen raphics – include insurance in ation unless the insurance di	) mL post-lab dr ntation formation. We v ctates otherwise : DMARDS and	will	
<ul> <li>Anaphylaxis Protocol: Epinephrine Auto-Injector dua Administer epinephrine IM in the event of anaphylaxis</li> <li>Therapy Specific Documentation</li> <li>Please include the following lab results required for infu are available, the following labs will be drawn prior to f</li> <li>Hepatitis B Surface Antigen</li> <li>Hepatitis B Core Antibody Total (not Core IgM)</li> <li>QuantiFERON TB</li> </ul>	. May repeat x usion. If no res irst infusion:	Heparin (10 uni Refill x one year 0.3mg Children: 0.15 mg (1 as needed, Call 911. Refined sults Builts H&P OR progre Medication List	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r effill x 1yr Other Required Document raphics – include insurance in ation unless the insurance di ss note(s) - please list past and present	) mL post-lab dr ntation formation. We v ctates otherwise : DMARDS and	will	
<ul> <li>Anaphylaxis Protocol: Epinephrine Auto-Injector dua Administer epinephrine IM in the event of anaphylaxis</li> <li>Therapy Specific Documentation</li> <li>Please include the following lab results required for infu are available, the following labs will be drawn prior to f</li> <li>Hepatitis B Surface Antigen</li> <li>Hepatitis B Core Antibody Total (not Core IgM)</li> <li>QuantiFERON TB</li> </ul>	. May repeat x usion. If no res irst infusion:	Heparin (10 uni <b>Refill x one yea</b> 0.3mg Children: 0.15 mg (1 as needed, Call 911. <b>Refill</b> sults <b>Patient Demogr</b> obtain authoriz H&P OR progre Medication List biologics below	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r effill x 1yr Other Required Document raphics – include insurance in ation unless the insurance di ss note(s) - please list past and present	) mL post-lab dr ntation formation. We v ctates otherwise : DMARDS and	will	
<ul> <li>Anaphylaxis Protocol: Epinephrine Auto-Injector dua Administer epinephrine IM in the event of anaphylaxis</li> <li>Therapy Specific Documentation</li> <li>Please include the following lab results required for infu are available, the following labs will be drawn prior to f</li> <li>Hepatitis B Surface Antigen</li> <li>Hepatitis B Core Antibody Total (not Core IgM)</li> <li>QuantiFERON TB</li> <li>Other:</li> </ul>	. May repeat x usion. If no res irst infusion:	Heparin (10 uni Refill x one year 0.3mg Children: 0.15 mg (1 as needed, Call 911. Refine sults Patient Demogration batain authoriz H&P OR progre Medication List biologics below ider Information Prov	10 mL before/after use and 10 its/mL) 3 to 5 mL final flush r efill x 1yr Other Required Documen raphics – include insurance in ation unless the insurance di ss note(s) - please list past and present with dates of discontinue, if	) mL post-lab dr ntation formation. We v ctates otherwise : DMARDS and	will	

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: \_\_\_\_

Date: \_\_\_\_\_

**CONFIDENTIALITY NOTICE**: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.